A groundbreaking study led by this year’s Nobel Laureate in Chemistry, David Baker, could revolutionize the way snakebites are treated, particularly in Africa, where venomous snakebites are a major public health crisis. Researchers have developed new proteins that neutralize deadly toxins found in snake venom, offering a safer, cheaper, and more effective alternative to traditional antivenoms. This discovery could save thousands of lives annually, especially in regions with limited access to healthcare.
Snakebites are a devastating problem worldwide, particularly in Africa, Asia, and Latin America. According to the World Health Organization (WHO), between 1.8 and 2.7 million people are bitten by venomous snakes each year, resulting in approximately 100,000 deaths and 300,000 permanent disabilities, such as amputations. Africa bears a significant burden of this crisis, with weak healthcare systems often unable to provide timely and effective treatment.
Currently, the only available treatments are antivenoms derived from animal plasma, which have several drawbacks. These treatments are expensive, can cause severe side effects, and are not always effective. Additionally, snake venoms vary widely between species, meaning antivenoms must be tailored to specific regions, further complicating treatment efforts.
The new study, published on January 15 in the journal Nature, offers a promising solution. A team of researchers, including Baker from the University of Washington School of Medicine and Timothy Patrick Jenkins from the Technical University of Denmark (DTU), used advanced artificial intelligence (AI) tools to design proteins that can neutralize toxins from deadly snakes, such as cobras. These proteins specifically target a class of toxins called three-finger toxins, which are often responsible for the failure of traditional antivenoms.
In laboratory tests, the AI-designed proteins provided complete protection against lethal doses of these toxins in mice, with survival rates ranging from 80% to 100%. While the proteins do not yet protect against full snake venom—a complex mixture of toxins unique to each species—this breakthrough demonstrates the potential of AI-driven protein design to combat harmful substances that have previously been difficult to neutralize.
One of the most significant advantages of this new approach is its simplicity and cost-effectiveness. Unlike traditional antivenoms, which require immunizing animals and extracting plasma, the new proteins can be produced using microbes. This method is not only cheaper but also faster, as the AI software drastically reduces the time needed to design and test effective molecules.
Susana Vazquez Torres, the lead author of the study and a researcher in Baker’s lab, emphasized the potential impact of this discovery. “Protein design will help make snakebite treatments more accessible for people in developing countries,” she said. “The antitoxins we’ve created are easy to discover using computational methods, cheap to produce, and robust in laboratory tests.”
Timothy Patrick Jenkins, an Associate Professor at DTU Bioengineering, highlighted another advantage: the small size of the designed proteins. “Because they are so small, we expect them to penetrate tissue better and neutralize toxins faster than current treatments,” he explained. This could lead to quicker and more effective relief for snakebite victims.
While the results are promising, the researchers caution that traditional antivenoms will remain the primary treatment for snakebites for the foreseeable future. However, the new proteins could initially be used as supplements to enhance the effectiveness of existing treatments. Over time, they may pave the way for next-generation therapies that are more affordable and accessible.
The implications of this research extend beyond snakebites. The AI-driven protein design approach could be applied to develop treatments for other diseases, including certain viral infections. By reducing the cost and resource requirements of drug discovery, this technology has the potential to make life-saving medicines more widely available, particularly in resource-limited settings.
“We didn’t need to perform several rounds of laboratory experiments to find effective antitoxins—the design software is so advanced that we only needed to test a few molecules,” said Baker. “This approach simplifies drug discovery and could help create affordable treatments for a wide range of diseases.”
For Africa, where snakebites are a persistent and deadly threat, this breakthrough offers hope for a future where effective treatments are within reach for all. By leveraging the power of AI and protein design, scientists are taking a significant step toward ensuring that no one has to suffer or die from a preventable cause like a snakebite.
